Tagged as: Hyrimoz

Biosimilar Regulatory Approval Updates

Teva announced today that the European Commission has granted marketing authorization for RANIVISIO, a biosimilar ranibizumab, for the treatment of age-related macular degeneration (AMD).  Teva entered into a strategic partnership with Bioeq AG for the exclusive commercialization of ranibizumab.  According to the press release, RANIVISIO (ranibizumab) will be the first…

Read More

European Commission Grants Marketing Authorization for Adalimumab and Trastuzumab Biosimilars

Last week the European Commission granted marketing authorization for two biosimilars. First, Sandoz, a division of Novartis, announced on July 27 that it had received marketing authorization for Hyrimoz, its adalimumab biosimilar to AbbVie’s Humira.  Authorization was granted for all indications of the reference biologic, including rheumatoid arthritis, plaque psoriasis,…

Read More